ArticleDiscover oncology2025
To explore the molecular mechanisms and shared genetic characteristics of rheumatoid arthritis and cervical cancer based on multiple omics and clinical samples.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe potential association between rheumatoid arthritis (RA) and cervical cancer risk is still debated and necessitates additional clinical investigations. This study aimed to explore this relationship using Mendelian randomization and multi-omics analysis, aiming to enhance insights and reduce redundancy.
methodsThis study employs a Mendelian randomization approach to investigate potential associations between rheumatoid arthritis (RA) and cervical cancer susceptibility. Single-cell enrichment scores were calculated using RA-specific transcriptome differentially expressed genes, and prognostic models were developed using 10 machine learning algorithms to assess cervical cancer differential gene expression associated with RA scores. Subsequently, differences in clinical characteristics, immune cell infiltration, immunotherapy efficacy, and response to chemotherapeutic drugs were analyzed between high- and low-risk groups of patients. Finally, the expression of model genes was verified by cervical cancer cell lines and clinical fresh samples.
resultsMendelian randomization has revealed an increased incidence of cervical cancer associated with RA. RA enrichment scores show predominant enrichment in the single-cell NK cell subpopulation. Cervical cancer can be distinctly categorized into two subgroups based on RA score-associated prognostic genes, demonstrating significant differences in immune cell infiltration and prognosis between these subgroups. Prognostic modeling indicates that patients in the low-risk group exhibit better prognosis, enhanced immune cell infiltration, and improved response to immunotherapy and drug treatments. Finally, multiple external data confirmed that there were significant differences in the expression of model genes.
conclusionRheumatoid arthritis is causally associated with the development of cervical cancer. Patients with rheumatoid arthritis have an increased risk of concurrent cervical cancer. Immune cell pathways, such as NK cell-based, may be important in increasing the risk of cervical cancer in RA patients. The abnormal expression of the model gene may be involved in the progression of cervical cancer patients and the impact of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.